PMGC | 10-Q: FY2025 Q2 EPS: USD -2.41

EPS: As of FY2025 Q2, the actual value is USD -2.41.

Segment Revenue

• Discontinued Operations (Skincare Business): Revenue for the six months ended June 30, 2025, was $152,381, compared to $1,220,093 for the same period in 2024.

Operational Metrics

• Net Loss: For the six months ended June 30, 2025, the net loss from continuing operations was -$2,160,301, compared to -$1,097,032 for the same period in 2024.
• Total Net Loss: For the six months ended June 30, 2025, the total net loss was -$2,170,810, compared to -$2,809,741 for the same period in 2024.
• Operating Expenses: Total operating expenses for the six months ended June 30, 2025, were $2,215,242, compared to $1,356,216 for the same period in 2024.

Cash Flow

• Operating Cash Flow: Cash flows used in operating activities for the six months ended June 30, 2025, were -$2,693,714, compared to -$3,104,757 for the same period in 2024.
• Free Cash Flow: Not explicitly stated, but cash used in investing activities was -$18,479 for the six months ended June 30, 2025.

Unique Metrics

• Research and Development Expenses: For the six months ended June 30, 2025, R&D expenses were $99,108, compared to $55,553 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: PMGC Holdings Inc. plans to increase revenue through PMGC Capital LLC by acquiring and managing undervalued assets and investments. The company also aims to advance clinical development for NorthStrive Biosciences, Inc.’s clinical assets toward IND applications.
• Non-Core Business: The company is evaluating potential opportunities such as out-licensing biotechnology applications, potential spin-offs, and creating new publicly traded companies, such as SPACs.